Podcasts about Prognosis

In this episode of the TrueBirth Podcast, Dr. Yaakov Abdelhak discusses two women diagnosed with second trimester PPROM who received completely different prognoses for very different clinical reasons. Through these stories, we explore one of the most important realities in obstetrics: the same diagnosis does not always mean the same outcome. From fluid levels and infection risk to fetal development and maternal health, this conversation highlights the nuance, complexity, and individualized decision making required in high risk pregnancy care. Got something you want to share or ask? Keep it coming. We love hearing from you. Email us or send a voice memo, and you might just hear it on the next episode. Don't forget to like, comment, and subscribe your questions could be featured in our next episode. For additional resources and information, be sure to visit our website at Maternal Resources: https://www.maternalresources.org/ You can also connect with us on our social channels to stay up-to-date with the latest news, episodes, and community engagement: YouTube: youtube.com/maternalresources Instagram: @maternalresources Facebook: facebook.com/IntegrativeOB TikTok: NatureBack Doc on TikTok Grab Our Book: The NatureBack Method for Birth—your guide to an empowered pregnancy and delivery. Shop now at naturebackbook.myshopify.com

Gareth, Justin, and Michael at Skewed and Reviewed look at Entertainment News for the week. 00:00 Movie and Game News 06:10 Box Office numbers 14:50 Fast and Furious streaming series 22:17 X-files update 31:00 TV/Streaming News

Ian's done a bit of spring cleaning, suspension refreshing, and playlist stacking. And Dave? He snagged some car photos that he knows Ian is going to love. We love you!

Research fellow, Adrian Chen, discusses a multicenter study evaluating myocardial PD‑L1 expression as a prognostic biomarker in immune checkpoint inhibitor–associated myocarditis. The conversation highlights how elevated myocardial PD‑L1 identifies patients at markedly higher risk for early adverse cardiac events and explores its potential role in improving risk stratification and guiding earlier, more aggressive therapy in this high‑risk population.

Will and Russ react to Iran's decision today to open the Strait of Hormuz. Also on the show: Europe's adolescent reaction to Trump's Iran rhetoric.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Shanshan Wu from the Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory of Digestive Health, National Clinical Research Center for Digestive Disease, Beijing, China, and Professor Yuanjie Pang from Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://bit.ly/4rRJeUI).

Leslie Kenny was told in her 30s that she had five years to live. Diagnosed simultaneously with lupus, rheumatoid arthritis, and Hashimoto's thyroiditis — and told to give up her dream of having children — she did what true Betties do: she refused the prognosis, threw everything she had at it, and got to work. Now 60 years old, Leslie reports a biological age of 21. She is autoimmune disease-free. And she naturally conceived a child at 43. Her recovery journey led her to collaborate with University of Oxford scientists and to discover spermidine — a naturally occurring, food-derived longevity compound that was hiding in plain sight. It's been in our food for millennia, it's in breast milk, and it's in every plant on earth. And it addresses 9 of the 12 hallmarks of ageing identified by science as the root causes of why we get older. For 20% off Primeadine, go to: https://www.oxfordhealthspan.com/DRSTEPHANIE  Episode Overview (timestamps are approximate): (0:00) Intro/Teaser (4:00) What Is Spermidine and Why Do We Lose It? (8:00) Autophagy, Hair, Nails & the Biological Dashboard (17:00) The 12 Hallmarks of Ageing, Explained for Real Life (23:00) mTOR, Muscle Loss, and Why Spermidine Is Different (27:00) Food Sources, Dosage & Lifestyle Levers (38:00) Leslie's Story: The Diagnosis, the Prognosis, the Refusal (55:00) IVIG, Trauma Therapy & the Surprise Pregnancy at 43 (1:18:00) Femspan, Future Research & Where to Find Leslie (1:22:00) The After-Party Thoughts with Dr. Stephani Resources mentioned in the Episode can be found at: https://drstephanieestima.com/podcasts/ep464  We couldn't do it without our sponsors: JUST THRIVE HEALTH - Take the Just Thrive FEEL BETTER challenge today, and save 20% on your first order. Go to https://justthrivehealth.com/better and use the code BETTER to see the difference for yourself. BON CHARGE - Achieve glowing skin, gain more energy, and uplevel your recovery practice with a suite of red light products. Get 15% off at https://boncharge.com/better with code BETTER. HIGHER DOSE - If you're noticing thinning, shedding, or simply want to support scalp and hair health proactively, this is a powerful addition to your routine. Get 15% off the Red Light Hat at https://higherdose.com with code BETTER at checkout. KENETIK - You think carefully about how you fuel your body but are you fueling your brain? Learn more about Kenetik and try it for yourself by going to https://drinkkenetik.com/BETTER and use code BETTER for 15% off QUALIA LIFE - Boost energy, DNA health, and cellular protection. Save 15% at https://qualialife.com/better with code BETTER. ****************************P.S. When you're ready, here are two ways Dr. Stephanie can help you:Subscribe: The Mini Pause — My weekly newsletter packed with the most actionable, evidence-based tools for women 40+ to thrive in midlife.Build Muscle: LIFT — My progressive strength training program designed for women in midlife. Form-focused, joint-friendly, and built for real results. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this SRNA "Ask the Expert" episode moderated by Krissy Dilger, Dr. John Chen of the Mayo Clinic answered audience questions about MOG antibody disease (MOGAD). He discussed diagnosis and the importance of titers and live cell-based assays given possible false positives [00:02:42]. Dr. Chen reviewed acute management with early high-dose steroids, prolonged tapers, and escalation to plasma exchange for severe or steroid-refractory attacks, as well as evolving long-term options including IVIG/subcutaneous IG and IL-6 blockade [00:04:14]. Audience questions covered relapse prediction, vision recovery timelines, fatigue, pregnancy, heredity, symptom interpretation, and whether to stop immunotherapy when antibodies become undetectable [00:12:13]. Finally, Dr. Chen described current and upcoming research, including a trial that is currently enrolling participants, and future prospects for optic nerve regeneration while cautioning against unproven stem cell clinics [00:41:37].John J. Chen, MD, PhD attended the University of Virginia for his undergraduate and combined MD/PhD degrees and completed his Ophthalmology residency and Neuro-Ophthalmology fellowship training at the University of Iowa. He then took a position at the Mayo Clinic in 2014 where he specializes in Neuro-Ophthalmology. Currently, he serves as a Consultant and Professor of Ophthalmology and Neurology, and Neuro-Ophthalmology Fellowship Director at the Mayo Clinic. Among Dr. Chen's awards and honors are the AAO Senior Achievement Award, Top Doctors in Minnesota, the Heed Fellowship, Real World Ophthalmology Inspiring Academic Leader Award, Ophthalmology Teacher of the Year Award four times leading to induction to the Educators Hall of Fame, and the Mayo Clinic Distinguished Educator Award – awarded to the top educator at Mayo Clinic in Rochester. He is an Associate Editor for Ophthalmology and the Journal of Neuro-Ophthalmology, has authored more than 250 peer-reviewed publications, and focuses his research on ophthalmic imaging, idiopathic intracranial hypertension, and optic neuritis, particularly NMOSD and MOG antibody–associated disease.00:00 Welcome and Introductions01:08 What Is MOGAD?02:42 Causes and Triggers03:23 How MOGAD Is Diagnosed04:14 Acute Attack Treatments06:35 Steroid Side Effects08:13 Testing During Treatment09:09 Long Term Therapies12:13 Interpreting MOG Positivity16:51 Eye Symptoms and Vision Fluctuations20:12 Antibody Titers and Severity21:19 Relapse Risk After First Attack23:09 Seizures and Encephalitis24:17 Vision Recovery After Optic Neuritis25:13 Acute Treatment Window25:57 Hereditary Risk Questions26:35 Stopping Azathioprine Safely29:56 Managing Post Attack Pain30:16 Steroids IVIG and Plasma Exchange32:08 Infections as Triggers33:01 Retesting MOG Antibodies35:01 Fatigue and Workup36:23 Prognosis and Life Expectancy37:45 Tinnitus and Brain Pressure39:05 Pediatric and Pregnancy Concerns41:37 Trials and Future Regeneration46:05 Research Resources and Wrap Up

Imaging techniques in multiple sclerosis are evolving rapidly, with MRI and emerging biomarkers playing a central role in diagnosis, prognosis and disease monitoring. In this episode of the ECTRIMS Podcast, neurologist Gabriel Bsteh and host Brett Drummond explore how MRI, optical coherence tomography (OCT), and imaging biomarkers are reshaping the way clinicians diagnose and manage MS. They discuss the 2024 updates to the McDonald diagnostic criteria, including the introduction of the central vein sign (CVS), paramagnetic rim lesions (PRL), and the inclusion of the optic nerve. The episode also examines how imaging biomarkers may be used to: Predict disease progression Provide prognostic information at diagnosis Monitor neuro-axonal damage over time Support treatment decisions and personalised medicine This episode is essential listening for anyone interested in multiple sclerosis, MRI, OCT, biomarkers, and advances in MS research and care.

Commentary by Dr. Jian'an Wang.

Send us Fan MailDeep Learning Can Predict the Overall Survival of Cervical Cancer Based on Histopathological Image, Gene Mutation and Clinical Information. Shen J, Miao Z, Wang L, et al. IET Systems Biology 2026.Episode Summary: In this deep dive, we explore a groundbreaking 2026 study that uses multimodal deep learning to act as a "master diagnostician" for cervical cancer. We examine what happens when an AI is fed a combination of standard clinical data, cutting-edge genetic sequencing, and century-old H&E tissue slides. The results force us to rethink how cancer operates: what happens when the genetic "blueprint" of a tumor lies to us, and the real biological truth is hiding in the seemingly chaotic pink and purple pixels of the connective tissue?In This Episode, We Cover:The Murky Diagnostics of Oncology: Understanding why predicting an individual patient's overall survival (OS) in cervical cancer is profoundly difficult. Getting this prediction wrong means risking either lethal undertreatment (distant metastasis) or subjecting stable patients to devastating overtreatment toxicities.The Three Modalities (The Suspect, The DNA, and The Security Footage):Clinical Data: The "suspect's description," utilizing standard patient metrics like age and tumor stage.Molecular Data: The genetic "blueprint" and somatic gene mutations. The AI isolated major red flags like RGR, DBN1, and CALCR mutations, which drive metastasis and signal poor prognosis.Histopathological Images (H&E): The "security footage" showing the physical tissue battlefield via whole slide images.The Model Showdown: Researchers trained a deep learning model (ResNet18) and fused these modalities using Multimodal Compact Bilinear (MCB) fusion. The AI was tasked with classifying patients into short-term (under 3 years) or long-term (over 3 years) survival, and it was rigorously validated on a completely independent dataset (PUMCH) to ensure generalizability.Round 1 - The Genetic Curveball: Despite being the cell's source code, genetic mutation data was the absolute worst predictor of survival, achieving an AUC of just 0.559. Adding it to the AI actually caused the "curse of dimensionality," making the model worse by overwhelming it with mathematical noise.Round 2 - The AI's "Aha!" Moment: The tissue phenotype dictates what actually happens. Fusing simple clinical data (age) with H&E images achieved a highly accurate 0.783 AUC. Even more shockingly, for aggressive short-term survival cases, the AI didn't focus heavily on the tumor itself. It looked at the stroma (connective tissue), deducing on its own that the host's inflammatory battleground dictates the lethality of the disease.The Future of the Lab: How automated quality control (HistoQC) and mathematical techniques (Macenko color normalization) strip away lab technician error and chemical dye variations. We also look ahead to how hyperspectral imaging might soon reveal the foundational chemical signatures of living cells.Key Takeaway: Throwing more data at an algorithm isn't always better. By successfully extracting profound biological truths from routine, inexpensive H&E slides, the AI proved that we don't necessarily need $1,000 genomic sequencing panels to accurately predict prognosis. The physical manifestation of the tumor microenvironment tells us exactly who is winning the battle, paving the way for accessible precision medicineSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Episode 217: Testicular Cancer Dr. Arreaza: Welcome to Rio Bravo qWeek Podcast. Today we are discussing testicular cancer, a topic that may not appear frequently in primary care but is extremely important to recognize early. We are joined by Brandon Noorvash and Dr. Ebenezer Dadzie. Please introduce yourselves. Brandon: Thank you, Dr. Arreaza. My name is Brandon Noorvash. I am a third-year medical student at Western University of Health Sciences with a strong interest in urology. Ebenezer: Thank you for having us. My name is Dr. Ebenezer Dadzie, and I am a PGY-1 resident in the Clinica Sierra Vista Family Medicine Residency Program. Dr. Arreaza: Testicular cancer represents about 1-2% of cancers in men, but it is the most common cancer in men between the ages of 15 and 40. The good news is that it is also one of the most curable cancers in medicine, especially when detected early. Let's start with a quick question for our listeners. If a 25-year-old man presents with a painless lump in his testicle, what diagnosis should immediately come to your mind? Ebenezer: Testicular cancer should always be high on the differential. While benign conditions can cause scrotal swelling, a painless testicular mass should be considered cancer until proven otherwise. Dr. Arreaza: I agree. Especially if we perform a physical exam and find that the mass is attached to the testicle. Why is this such an important diagnosis for primary care physicians to recognize, what do you think, Brandon? Brandon: Testicular cancer typically affects young, otherwise healthy men, and early detection dramatically improves outcomes. Patients may delay seeking care because the lump is painless or because they feel embarrassed discussing symptoms. However, when diagnosed early, the 5-year survival rate exceeds 95%, and in localized disease it approaches 99%. Dr. Arreaza: Exactly, the survival is incredible and it gets even better with early detection. How common is testicular cancer? Ebenezer: In the United States, approximately 10,000 new cases are diagnosed each year, with around 500 deaths annually. The relatively low mortality reflects how effective current treatments are, especially chemotherapy for germ cell tumors. Dr. Arreaza: Let's talk about risk factors. What should clinicians know about risk factors for testicular cancer? Who is at risk? Brandon: The most important risk factor is cryptorchidism, or undescended testicle. Men with a history of cryptorchidism have about a 4-to-8-fold increased risk of developing testicular cancer. Ebenezer: Other risk factors include family history, personal history of testicular cancer, infertility, testicular atrophy, and certain genetic conditions such as Klinefelter syndrome. However, many patients who develop testicular cancer have no clear risk factors. Dr. Arreaza: Brandon, you recently saw a patient with testicular cancer during your rotation. Can you briefly tell us about that case? Protected health information is not being revealed, so patient confidentiality is being respected during this discussion. Dr. Arreaza: I think we all were pleasantly surprised to know that lung metastasis did not place the patient in a higher risk category. On the other hand, nonpulmonary visceral metastases (such as liver, bone, or brain) define poor-risk disease in nonseminoma and intermediate-risk disease in seminoma.  Dr. Arreaza: And of course, if the patient presents with sudden severe pain, we should always think about testicular torsion, which is a surgical emergency. What should clinicians focus on during the physical exam? Ebenezer: Testicular tumors typically feel firm, irregular, non-tender, and located within the testicle itself. Brandon: A helpful exam pearl is transillumination. Fluid-filled structures like hydroceles will transilluminate, whereas solid tumors do not. Dr. Arreaza: I have to admit I've never done a transillumination in a scrotum before.  Brandon/Ebenezer: I've done it. I had to clean my pen light afterwards. Arreaza: Once you suspect testicular cancer, what is the next step in evaluation? Ebenezer: The first diagnostic test is a scrotal ultrasound. Ultrasound is highly sensitive and can determine whether the mass is intratesticular, which is highly suspicious for malignancy. Dr. Arreaza: US and tumor markers. Let's talk a bit more about tumor markers. Why are they useful in testicular cancer? Brandon: Tumor markers help with diagnosis, staging, and monitoring response to treatment. Ebenezer: Alpha-fetoprotein, or AFP, is typically elevated in non-seminomatous germ cell tumors, particularly yolk sac tumors. An important point is that pure seminomas do not produce AFP. Brandon: Beta-hCG can be elevated in both seminomas and non-seminomatous tumors, although the levels are often higher in the non-seminomatous types. Ebenezer: LDH is less specific but can reflect tumor burden and disease activity, so it's useful for monitoring progression or response to treatment. Dr. Arreaza: So, tumor markers are not only diagnostic tools, but they also help guide staging and follow-up care. That's an important board question. Why don't we perform a biopsy in a testicular mass?  Ebenezer: Testicular masses suspicious of cancer are not biopsied because biopsy can disrupt lymphatic drainage and potentially spread tumor cells. Instead, the standard treatment is radical inguinal orchiectomy, which both removes the tumor and establishes the diagnosis. Dr. Arreaza: Brandon, can you briefly explain the two main categories of testicular cancer? Brandon: Let's start with the germ cell tumors. They are broadly divided into seminomas and non-seminomatous germ cell tumors (NSGCT). Seminomas tend to grow more slowly and are highly sensitive to radiation therapy. Ebenezer: Non-seminomatous tumors include embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. These tumors tend to be more aggressive but are still highly responsive to treatment. Dr. Arreaza: How are patients staged once the diagnosis is made? Ebenezer: Staging typically includes a CT scan of the chest, abdomen, and pelvis to evaluate for metastasis, especially to the retroperitoneal lymph nodes, which are the most common site of spread. Dr. Arreaza: And how is testicular cancer managed? Brandon: The initial step is almost always radical inguinal orchiectomy. Depending on staging and tumor type, treatment may include active surveillance, chemotherapy, radiation therapy, or retroperitoneal lymph node dissection. Ebenezer: One reason outcomes are so favorable is that germ cell tumors respond extremely well to cisplatin-based chemotherapy. Dr. Arreaza: Let's talk about prognosis. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _________________________________________ References: Honda K, Kawai T, Taguchi S, Shiratori T, Miyakawa J, Nakamura Y, Kaneko T, Suzuki K, Suda S, Kamei J, Kakutani S, Niimi A, Yamada Y, Urakami S, Fukuhara H, Nakagawa T, Kume H. Impact and Risk Factors of Diagnostic Delay in Patients With Testicular Cancer: A Multicenter Retrospective Study. Int J Urol. 2025 Nov;32(11):1593-1601. doi: 10.1111/iju.70187. Epub 2025 Jul 28. PMID: 40726135; PMCID: PMC12586796. https://pubmed.ncbi.nlm.nih.gov/40726135/ Singla N, Bagrodia A, Baraban E, Fankhauser CD, Ged YMA. Testicular Germ Cell Tumors: A Review. JAMA. 2025;333(9):793–803. doi:10.1001/jama.2024.27122 https://jamanetwork.com/journals/jama/article-abstract/2829847?utm_source=openevidence&utm_medium=referral Chavarriaga J, Nappi L, Papachristofilou A, Conduit C, Hamilton RJ. Testicular cancer. Lancet. 2025 Jul 5;406(10498):76-90. doi: 10.1016/S0140-6736(25)00455-6. Epub 2025 May 29. PMID: 40451233. https://pubmed.ncbi.nlm.nih.gov/40451233/ Tateo V, Thompson ZJ, Gilbert SM, Cortessis VK, Daneshmand S, Masterson TA, Feldman DR, Pierorazio PM, Prakash G, Heidenreich A, Albers P, Necchi A, Spiess PE. Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review. Eur Urol. 2025 Apr;87(4):427-441. doi: 10.1016/j.eururo.2024.10.023. Epub 2024 Nov 13. PMID: 39542769. https://pubmed.ncbi.nlm.nih.gov/39542769/ Langn RC, Puente MEE. Scrotal Masses. Am Fam Physician. 2022 Aug;106(2):184-189. PMID: 35977130. https://pubmed.ncbi.nlm.nih.gov/35977130/ Xu P, Wang J, Abudurexiti M, Jin S, Wu J, Shen Y, Ye D. Prognosis of Patients With Testicular Carcinoma Is Dependent on Metastatic Site. Front Oncol. 2020 Jan 10;9:1495. doi: 10.3389/fonc.2019.01495. PMID: 31998648; PMCID: PMC6966605. https://pubmed.ncbi.nlm.nih.gov/31998648/

Tiger Woods made an unexpected "return" to "professional golf" on Tuesday night, so Andy and Brendan! once again went LIVE on YouTube in his honor. They initially react to LAGC's blowout win over Jupiter Links in Match 2 of the TGL Finals, ending Tiger's comeback early and sending Tom Sim packing until next season. There are takeaways from the second season of TGL, ideas for the league's future, and more questions about when we'll see Tiger next. Andy submits that the only question remaining should be whether Woods can make the cut at the Masters, not whether he can compete or even finish four days of competition. Speaking of Augusta, that's the next time Scottie Scheffler will play following a WD before this week's Houston Open. Houseplant #2 is arriving at the Scheffler household just in time for Scottie's latest attempt at a green jacket. Without the Sheriff in town, Brendan runs through some notables for this week's Tour event and breaks the news of Deputy Sam Burns's new job at Raising Cane's! Andy shares his 5 Guys to Monitor as we approach crunchtime for those not yet in the Masters field. Andy and Brendan end up with the same one-and-done pick for the wide-open setup at Memorial Park, but PJ ends up using a big gun to even things out. Elsewhere on the Schedule for the Week, the DP World Tour is leaning into the absurdity of DLF and has captivated Andy with an 18-hole flyover of perhaps the best course in the world. However, the "Event of the Week" has lost some shine as a podcast favorite is not playing in this year's Indian Open. Lastly, Brendan brings this rambling episode home with yet another Masters Fact of the Day with just two weeks to go until the first major of the year.

032426 Scott Adams Show, Iran War Analysis, Prognosis for a Deal, American Media Sides with Iran

Matt Spiegel and Laurence discussed how the Cubs got good news in learning that right fielder Seiya Suzuki suffered a PCL strain in his right knee rather than something more serious.

In this episode of the Optimal Body Podcast, Dr. Jen and Dr. Dom, both doctors of physical therapy, break down cervical radiculopathy—commonly referred to as a “pinched nerve” in the neck. They explain the symptoms and causes of a pinched nerve, and discuss why imaging findings aren't always alarming. The hosts share practical strategies for relief, including targeted exercises, posture tips, and gentle nerve mobilization, while emphasizing the importance of conservative care and when to seek urgent medical attention for a pinched nerve. Their accessible, stepwise approach empowers listeners to manage neck and arm pain confidently and safely, promoting resilience and recovery through education and movement. Lifting for Longevity Course Discount! Come and join our brand new course Lifting for Longevity! This course was created by Doc Jen and shot with her 73 year old mother to show that, regardless what age or level you are, you can build strength, power, mobility, balance, and so much more! It will help you understand all of the components of movement that are important when it comes to moving well, late in life. Come join us and grab a bonus discount with code OPTIMAL at checkout! We think You'll Love: Lifting for Longevity Course Jen's Instagram Dom's Instagram YouTube Channel What You'll Learn: 03:26 Breaking Down the Medical Terminology 04:29 Symptoms and Causes 07:51 Imaging Findings and Asymptomatic Cases 08:55 Diagnosis and Clinical Assessment 11:01 Role of Imaging and When to Use It 12:01 Prognosis and Recovery Timeline 14:21 Active vs. Passive Treatments 15:35 Pillar 1: Education and Symptom Management 17:02 Pillar 2: Movement and Exercise Strategies 21:10 Exercise Demonstrations and Recommendations 23:54 Pillar 3: Nerve-Friendly Loading and Neurodynamics 27:09 Pillar 4: Manual Therapy as an Adjunct 29:30 List of urgent symptoms and red flags that require immediate medical attention. For full show notes and resources visit https://jen.health/podcast/452 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Sam Ashoo, MD and Dr. Dana Klavansky, MD discuss the March 2026 Emergency Medicine Practice article, Emergency Department Evaluation and Management of Severe Traumatic Brain InjuryIntroduction & Welcome (0:15)Guest Introduction (0:55)Epidemiology of Severe TBI (2:37)Pathophysiology: Primary vs. Secondary TBI (4:24)Types of Hemorrhage and Hematomas (5:25)Classification (7:31)Mild vs. Moderate vs. Severe TBIImpact Loading vs. Inertial LoadingDifferential Diagnosis (9:22)Prehospital Care (9:42)Emergency Department History (13:33)Diagnostics (15:13)CT Scan and the A-B-B-B-C ApproachRepeat CT TimingBedside Ultrasound for Optic Nerve Sheath DiameterPupillometryBiomarkersTreatment (24:52)Airway ManagementVentilation and CO2 TargetsHyperosmolar Therapy: Hypertonic Saline and MannitolCerebral Perfusion PressureBlood Pressure GoalsTemperature ManagementCoagulopathy ManagementSeizure Prophylaxis and EEG MonitoringTiered ICP Management (35:29)Surgical Indications (38:40)Prognosis (40:33)Special Topics (41:30)Sports Injuries and CTETranexamic Acid (CRASH-3 Trial)Wrap-Up (43:46)Subscribers, take the CME test here. Emergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net

Trump's war against Iran is shifting the geopolitical landscape in the Middle East - but how much has really changed in US foreign policy? What is different about this conflict compared to previous decades? What does this mean for our allies, and what role does Israel play in Trump's decision-making? Max Boot, Aaron David Miller, and Holly Dagres join David Rothkopf to take stock of America's war in Iran. Learn more about your ad choices. Visit megaphone.fm/adchoices

Trump's war against Iran is shifting the geopolitical landscape in the Middle East - but how much has really changed in US foreign policy? What is different about this conflict compared to previous decades? What does this mean for our allies, and what role does Israel play in Trump's decision-making? Max Boot, Aaron David Miller, and Holly Dagres join David Rothkopf to take stock of America's war in Iran. Learn more about your ad choices. Visit megaphone.fm/adchoices

Buy/Stream: https://music.retroidmusic.com/pgn086 A deep, dark progressive breaks take on “Kasado” by Jon Towell released on Prognosis.

In this episode, Candice sits down with Mark Ruegg, a stage four pancreatic cancer thriver, holistic healing advocate, and co-founder of Boom Mar Productions. Mark shares how his life took an unexpected turn from building a successful career in child wrangling and production services to facing a terminal cancer diagnosis with only months to live. In this episode, they discuss:Mark's unexpected stage four pancreatic cancer diagnosis and prognosisHow surrender and trust became a foundation for healingThe role of meditation and Dr. Joe Dispenza's work in his recoveryWhy the body cannot heal in fight or flight modeThe importance of nutrition, movement, and lowering inflammationHow belief and positivity became essential ingredients in his healing journeyMark's mission to help others see that healing is possible This inspiring conversation is a powerful reminder that when belief and possibility outweigh the prognosis, healing, purpose, and hope can emerge in extraordinary ways. About Mark:Mark Ruegg is a Stage IV pancreatic cancer thriver, holistic healing advocate, and co-founder of BuMar Productions, a leading child wrangling and production services referral agency trusted by Disney, Walmart, and Target. Defying a grim prognosis through advanced medicine, spiritual faith, and transformative holistic practices, Mark inspires cancer patients and caregivers to believe healing is possible. With nearly 20 years in advertising and a passion for empowering others, he shares a message of hope, resilience, and active healing. Mark's story was recently featured in the Seena Magowitz Foundation's "Warriors" series, highlighting his commitment to helping others embrace their power to heal. Facebook: https://www.facebook.com/markallenrueggIG: https://www.instagram.com/markallenruegg/Substack: https://substack.com/@markruegg-----Connect with Candice Snyder!Website: https://www.podpage.com/passion-purpose-and-possibilities-1/Facebook: https://www.facebook.com/candicebsnyder?_rdrPassion, Purpose, and Possibilities Community Group: https://www.facebook.com/groups/passionpurposeandpossibilitiescommunity/Instagram: https://www.instagram.com/passionpurposepossibilities/LinkedIn: https://www.linkedin.com/in/candicesnyder/Shop For A Cause With Gifts That Give Back to Nonprofits: https://thekindnesscause.com/Fall In Love With Artists And Experience Joy And Calm: https://www.youtube.com/@movenartrelaxation

What do you do when doctors give you five years to live… and you're still here more than twenty years later? In this moving episode of Contagious Influencers of America, nine-time Emmy winner David Sams interviews singer-songwriter and worship leader Tim Timmons. Diagnosed with incurable cancer in 2001 and given just five years, Tim's story deepened into one of profound faith, surrender, and hope. Now, over two decades later, his journey is portrayed by Milo Ventimiglia (Gilmore Girls, This is Us) in "I Can Only Imagine 2," tied to MercyMe's iconic song that has impacted millions "Even If." Tim shares openly about: Living with cancer while embracing both grief and hope Shifting from "working for God" to simply joining Jesus His daily grounding practice (the X he writes on his wrist each morning) Co-writing "Even If" with MercyMe's Bart Millard Watching his life and pain depicted on the big screen The heart of his new book, Waking Up Again: A Journey of Grief and Gratitude This isn't about pretending life is easy—it's about waking up again to presence, purpose, and a faith that holds joy and sorrow together. If you're facing uncertainty, loss, or a heavy season, this conversation will meet you with real hope. I Can Only Imagine 2 opens in theaters this Friday! "Waking Up Again" is available now wherever books are sold. Listen today—and share with someone who needs encouragement. Click here for tickets:  I Can Only Imagine 2 | Only In Theaters February 20 #PodcastInterview #FaithAndHope #WakingUpAgain #ICanOnlyImagine2 #EvenIf #GriefAndGratitude #TimTimmons #MercyMe #DavidSams #KeepTheFaith

Dr. Frank Peacock and Dr. Damon R. Kuehl join BioTalk for a focused discussion on one of emergency medicine's most persistent challenges: accurately diagnosing and predicting outcomes in mild traumatic brain injury. As Scientific Advisory Board members for BrainBox Solutions, Inc., they walk through what happens when a patient presents to the emergency department after a fall or sports injury and why current tools, including CT scans, often leave clinicians without clear answers. The conversation explores the gap between a "normal" scan and ongoing symptoms, and what missed or uncertain diagnoses can mean for patients weeks later.   Dr. Peacock outlines the HeadSMART II study and explains why combining blood biomarkers with neurocognitive testing provides a more complete assessment than biology alone. Dr. Kuehl discusses how multi-modal data, integrated through artificial intelligence, can generate an objective score to support real-time clinical decision-making and help identify patients at risk for persistent symptoms. The episode also highlights BrainBox's leadership, including CEO Donna Edmonds, a member of the BioHealth Innovation Board of Directors, and the company's role in advancing objective mTBI testing.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Dr. W. Frank Peacock IV is Professor of Emergency Medicine at Baylor College of Medicine. Chief Medical Officer at AseptiScope, and the founder of both a contract research organization called Comprehensive Research Associates, LLC and a medical education company named Emergencies in Medicine, LLC. Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital. He has >900 peer reviewed publications and is also the co-editor of multiple medical textbooks on heart failure, acute coronary syndromes, and traumatic brain injury.   Dr. Damon R. Kuehl is the Vice Chair of Research and Academic Affairs and Professor in the Department of Emergency Medicine at Virginia Tech, School of Medicine. He completed Medical School at University of Minnesota Medical School and his Emergency Medicine Residency at Stanford University. He has also completed residencies in Preventive Medicine and a Research Fellowship in the Center for Policy and Research in Emergency Medicine, at Oregon Health and Science University. Dr. Kuehl's research primarily focuses on diagnostic and prognostic uncertainty in brain injury. He is a lead investigator for HeadSMART II and for HeadSMART Geriatrics, a NINDS funded 3 year study to develop a diagnostic tool for head trauma in older adults.  He is the founder of the Carilion Brain Injury Center and also an investigator with the Virginia Tech Center for Biomechanics studying the boundary conditions associated with injuries in older adult falls.

The Unofficial Bengals continues its commitment to entertaining, thought-provoking Bengals talk. This episode focuses on the defense and special teams, where we give the group a grade, explain why, go over each player's performance and prognosis for 2026, as well as draft picks and free agents we should consider bringing into each defensive position group. This is your offseason Bengals fix while we watch 2 QB's not as good as ours compete in the Super Bowl! No one talks Bengals roster quite like The Unofficial Bengals Podcast!! Learn more about your ad choices. Visit megaphone.fm/adchoices

Fetal Microcephaly has an incidence of 2 to 12 in10,000 births in the USA and can be diagnosed prenatally via ultrasound (in second or early third trimester) or postnatally via measurement of head circumference (HC).  Antepartum, this is a unique diagnosis since we are mainly used to using PERCENTAGES for biometrics and for fetal weight, butmicrocephaly is not diagnosed by HC percentage- but by Standard Deviation (SD). Microcephaly has been linked to developmental delay, seizures, as well as feeding, vision and hearing problems.  Prognosis depends on the severityof the microcephaly and whether it is associated with other anomalies. What SD is diagnostic of microcephaly? What are the potential etiologies? What genetic syndromes are most associated with true microcephaly? Is fetal cranial MRIrecommended? Listen in for details. 1.     Sukenik-Halevy R, Golbary Kinory E, Laron KenetT, Brabbing-Goldstein D, Gilboa Y, Basel-Salmon L, Perlman S. Prenatalgender-customized head circumference nomograms result in reclassification ofmicrocephaly and macrocephaly. AJOG Glob Rep. 2023 Jan 29;3(1):100171. doi:10.1016/j.xagr.2023.100171. PMID: 36864987; PMCID: PMC9972400.2.     SOGC CO (2019) No. 380-Investigation andManagement of Prenatally Identified Microcephaly3.     Fetal Medicine Foundation: Microcephaly; https://fetalmedicine.org/education/fetal-abnormalities/brain/microcephaly

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027.From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Prognosis The American Pink Floyd has been performing the  music of Pink Floyd with incredible album accuarcy for 15 years both in the USA and internationallyKnown for their elaborate lights, lasers, and video projections Prognosis The American Pink Floyd is considered to be the best and most accurate ​Pink Floyd experience.On this episode we talk with keyboardist Rob Russell from Prognosis! UPCOMING SHOWS 2026 Tri state tour datesSaturday 2/21 Westport VFWSaturday 3/21 The Town Crier in Beacon, New YorkOutdoor Show in West Harrison, NY this summerMore coming soon! To Purchase tickets to The Westport VFW which is open to the public buy here! https://www.prognosismusic.com

The Unofficial Bengals Podcast reviews all aspects of the Bengals 2025 offense and offers a prognosis of the 2026 offense from the perspective of someone who lived and died with every snap in 2025. A 30-minute jaunt through the Bengals offense to get you through the dark days of no Bengals! No one talks Bengals quite like The Unofficial Bengals Podcast!! Learn more about your ad choices. Visit megaphone.fm/adchoices

What if the timeline you were given isn't a prediction of your future but simply a rough guess based on other people's outcomes?In this powerful episode of Renegade Remission, we explore why medical prognoses so often miss the mark, not because doctors are careless, but because human biology is far more adaptive and unpredictable than survival statistics can capture.You'll learn how prognoses are actually created, why they fail so frequently across cancer, neurodegenerative disease, heart failure, and chronic illness, and what science reveals about the people who outlive even the most sobering predictions.Through a documented case of unexpected survival and clear explanations of immune function, stress physiology, epigenetics, and functional status, this episode reframes prognosis as information, not fate.In this episode, you'll discover:Why prognoses are based on population averages — not individual biologyHow often doctors get life expectancy wrong (and why that matters for you)The biological factors that allow some people to far outlive expectationsWhy function, resilience, and internal environment matter more than a single diagnosisHow the immune system, nervous system, microbiome, and gene expression can shift over timeSimple ways to support the same internal pathways seen in people who become medical “surprises”This episode isn't about denying reality, it's about understanding it more fully.Listen now to release the weight of a timeline that may not belong to you, and to reconnect with the truth that biology is dynamic, adaptable, and full of possibility. Whether you're facing cancer, a neurodegenerative disease, heart disease, or another serious diagnosis, this episode offers clarity, grounding, and a renewed sense of what may still be possible.DisclaimerThis podcast is for educational purposes only and does not offer medical advice. Consult your licensed healthcare provider before making any changes to your treatment or health regimen. Reliance on any information provided is solely at your own risk.This podcast explores stories and science around ALS, dementia, MS, cancer, mind-body recovery, healing, functional medicine, heart disease, regression, remission, integrative medicine, autoimmune conditions, chronic illness, terminal disease, terminal illness, holistic health, quality of life, alternative medicine, natural healing, lifestyle medicine, and remission from cancer — offering hope and insight for those seeking resilience and renewal.

P.M. Edition for Jan. 15. As President Trump weighs whether to strike Iran, he's been advised that a large-scale strike against the country would be unlikely to make the regime fall, U.S. officials said. WSJ national security reporter Alex Ward says that doesn't mean that military action is off the table. Plus, an Arizona mine that became the first new source of U.S. copper in decades has a new big customer: Amazon. Journal reporter Ryan Dezember discusses what's going on in the U.S. copper industry. And there's new charges in the basketball betting scandal that is now one of the most sprawling gambling cases in the history of American sports. Alex Ossola hosts. Alternative Indicators: What's Dr. Copper's Prognosis for the U.S. Economy? Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode DescriptionIn this episode of the Lead Ministry Podcast, Josh Denhart and guest Vance Martin kick off a New Year series on productivity and progress in ministry. They introduce Vance's “Progress Spiral,” a simple framework to evaluate, strategize, and execute in your ministry, starting with a deep dive into the probe phase. They explore how to honestly assess your people, processes, and programs across three core cultures – volunteers, parents, and kids – offering practical language and real stories to help ministry leaders diagnose what is actually happening on the ground before they start fixing anything.If you've ever felt stuck in the same problems year after year, or frustrated that your changes never quite solve the real issues, this episode will equip and inspire you with a simple way to evaluate your ministry with clarity and courage.Key Topics CoveredThe Progress Spiral – a three-part framework for ongoing ministry improvement.The Probe Phase – evaluating people, processes, and programs without fear or assumptions.Hearing Hard Truth – why asking volunteers, parents, and kids for feedback builds trust and real change.Key Quote"Prognosis without diagnosis is malpractice."Scripture ReferencesProverbs 27:23 – "Know well the condition of your flocks, and give attention to your herds."Luke 14:28 – "For which of you, desiring to build a tower, does not first sit down and count the cost."TakeawayBefore you rewrite your calendar, overhaul your programs, or launch something new, you must slow down and see reality as it is. When you humbly probe your people, processes, and programs – and invite honest feedback from those you serve – you discover where the real problems are and where God may be inviting you to grow. Diagnosis comes before prescription, and good leaders are willing to ask hard questions and listen well.Call to ActionWe hope this episode encourages and equips you. Share it with a friend and stay tuned for more resources each week.Stay Connected for More ResourcesVisit our website: http://leadministry.comFollow us on Facebook: https://www.facebook.com/LeadVolunteersFind us on Instagram: https://www.instagram.com/leadvolunteers

When should an antibiotic allergy actually be tested? In this episode of the BackTable ENT Podcast, guest host Dr. Basil Kahwash, an allergist and immunologist at Ohio ENT & Allergy, sits down with Dr. Cosby Stone, an allergist and immunologist at Vanderbilt University Medical Center, to discuss antibiotic allergies and how to distinguish true allergies from intolerances. --- SYNPOSIS Dr. Stone breaks down common misconceptions around antibiotic allergies, with a focus on penicillin and cephalosporins. The conversation explores how these allergies are evaluated, including when skin testing is appropriate, why inaccurate allergy labels matter, and how confirmed allergies should be managed long term. They also dive into more advanced topics such as drug desensitization, current research in the field, and where the future of drug allergy evaluation is headed. --- TIMESTAMPS 00:00 - Introduction 01:03 - Understanding Antibiotic Allergies07:28 - The Importance of Accurate Allergy Diagnosis10:55 - Key Questions for Diagnosing Allergies17:10 - Implementing Allergy Testing in Healthcare Settings19:06 - Identifying Severe Allergic Reactions26:31 - Interpreting Allergy Skin Testing Procedures33:17 - Penicillin and Cephalosporin Cross-Reactivity37:15 - Drug Desensitization: Indications and Process40:30 - Prognosis and Long-Term Outcomes of Drug Allergies47:22 - Conclusion and Final Thoughts --- RESOURCES Dr. Basil Kahwash https://www.ohioentandallergy.com/physicians/basil-kahwash-md/ Dr. Cosby Stonehttps://www.vanderbilthealth.com/doctors/stone-cosby

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JZU865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 18, 2026.Addressing un-MET Needs in NSCLC: Elevating MET-Targeting Options for Patients With a Poor Prognosis In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and MET Crusaders. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AbbVie.Disclosure information is available at the beginning of the video presentation.

Optimistic bias by a family member charged with healthcare decisions can be a barrier for your wishes to be carried out. Learn how to avoid it in your advance care planning: https://bit.ly/499XQqaWhen Families Don't Hear the Truth: Why We Ignore Poor Prognoses  When someone we love is critically ill, we hang on every word from the medical team. But research shows something surprising and unsettling: when the prognosis is poor, many families simply don't hear it. Not because they aren't listening, and not because doctors aren't communicating clearly, but because human psychology steps in to protect us from unbearable news. Learn Important Facts to Guide You in Your Advance Care Planning Listen to learn more about this phenomenon and important considerations when you chose your healthcare decisionmaker. We also rebroadcast the S4E52 episode about preparing your paperwork for decisionmakers to speak for you when you are unable to.#AdvanceCarePlanning #EndofLife #ICU #HealthcareProxy #DurablePowerofAttorney #HealthcareDecisions #EveryoneDiesthePodcast #EveryDayisaGift #LivingWill #AdvanceDirective #PoorPrognosisIn this Episode:00:20 - How Appointed Decision Makers Interpret Information About Prognosis01:51 - Why Do Some Family Members Push for Every Possible Treatment When Further Interventions are Futile?03:35 - How Unrealistic Optimism Affects Decisions in the ICU07:36 - Intro - S4E52 - Durable Power of Attorney12:40 - Overlooked No More: Cordell Jackson20:36 - Are You Prepared to Die?  Get Ideas for Your Advance Care Planning 22:54 - The Importance of an Advance Directive39:47 - Advance Care Planning Example - How to Be Thorough and Precise 50:44 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

In part six of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss the prognosis of functional neurologic disorders.  Show citation:  Gelauff J, Stone J. Prognosis of functional neurologic disorders. Handb Clin Neurol. 2016;139:523-541. doi:10.1016/B978-0-12-801772-2.00043-6  Show transcript:  Dr. Jon Stone: This is Jon Stone with the Neurology Minute. Gabriela Gilmour and I are back to continue with part six of our seven-part series on FND. Today we're going to talk about prognosis. What's the outlook for people with FND? It's obviously a question that patients and relatives desperate to know the answer. Gabriela, what do you say to your patients with FND when they say, "What's going to happen to me? Dr. Gabriela Gilmour: That's a difficult question because the prognosis is variable and I'll talk in a moment about what we know about prognosis from the literature. But I think when patients ask me what's going to happen, I try to instill hope because we do know that this is a condition that can improve and it can improve, especially when patients have access to rehabilitation programs or psychotherapy or other treatment plans. So I try to emphasize that piece and emphasize hope when I'm talking about that with my patients. But if we sort of take a step back and we look at what is the overall prognosis from what we know in the literature with FND, fundamentally, FND for many is a chronic and often relapsing condition. As I mentioned, it can certainly improve with rehabilitation. A challenge is that most of our published studies on the prognosis of FND really come from a time when we knew a lot less about the condition and we had fewer treatment options. So these studies are somewhat difficult to apply today, but in these studies, we see that at least without treatment, most patients are the same or worse at follow-up. However, now we're starting to develop more rehabilitation programs and we have more evidence that shows that people certainly improve with rehabilitation and with therapy. There are some factors that I try to emphasize to patients as being good prognostic factors when I'm talking with them. These may be things like younger age, a shorter duration between symptom onset and diagnosis and patient agreement with the diagnosis or the perception of having control over their illness. When these types of things are present, I try to highlight them to, again, help build that hope for recovery. The one thing that I would also add maybe a bit of a different question, but I think is important to mention is that we as neurologists still have a lot to provide to our patients, even those who may not see much recovery in their symptoms and live with chronic illness. It's really important to consider that regular check-ins. In these check-ins, we can monitor for changing perpetuating factors. We can facilitate social services, mobility aids that help overall quality of life. We can still offer a lot to our patients. The other piece that I would mention too is that our patients are at risk of iatrogenic harm. So there is definitely a role for the neurologist to look at, are there medications that might not be indicated that are causing harm? Are there other things that we can communicate clearly with other care providers to make sure that we reduce that risk for our patients? Dr. Jon Stone: So it's about balancing some realism, but also making sure the patient doesn't lose hope. A good outcome isn't always necessarily that symptoms gone away. It might be similar to other chronic neurological conditions that we look after where we're okay with an outcome where the patient still has symptoms if they understand their condition and can learn to live with it better. We'll be back for our final Neurology Minute episode on FND with myself and Gabriela Gilmour talking about future directions in FND. Thanks for listening.

December 15, 2025 - Season 16, Episode 63 of The Terrible Podcast is now in the can. In this Monday morning episode, Alex Kozora and I get right to talking about the Pittsburgh Steelers as they prepare to play the Miami Dolphins Monday night to close out Week 15 of the 2025 NFL regular season. Alex and I quickly update the latest concerning Steelers OLB T.J. Watt, who is currently recovering from a partially collapsed lung that happened during a procedure late last week. We discuss Watt being officially ruled out for the Monday night game versus the Dolphins and what his prognosis for more missed games may or may not be. In addition to Watt, the Steelers have two other players that have been ruled out for Monday night in addition to two others being listed as questionable. Those two questionable players are DT Derrick Harmon (knee) and RB Jaylen Warren (illness), who was added to the team's injury report during this show. The Steelers are sure to have some transactions announced on Monday so Alex and I go over what those moves might possibly look like. We do, however, get news during the show that WR Marquez Valdes-Scantling will be signed off the team's practice squad later in the day. After going over a lot of housekeeping early in this show, Alex and I then welcome Hal Habib back to the podcast. Habib covers the Dolphins for The Palm Beach Post, and he is in Pittsburgh on Monday to cover the Monday night game. We spend 30 minutes with Habib discussing the Dolphins season to date in addition to previewing the Monday night game between Miami and Pittsburgh. He gives us his insight into the Dolphins when it comes to both sides of the football ahead of the Monday night game. At the end of our interview with Hal, he kindly gives us his score prediction for the Monday night game. If not already doing so, please follow Hal on Twitter/X at @gunnerhal and please make sure to read his work online here: https://www.palmbeachpost.com/staff/3294661001/hal-habib/. After finishing our interview with Hal, Alex and I then give our breakdown and complete preview of the Monday night game between the Steelers and the Dolphins. We also give out score predictions for the Monday night game to wrap up that segment. Finally, Alex and quickly go over what else transpired in the NFL on Sunday and how the Week 18 game between the Steelers and the Baltimore Ravens still figures to be one where the winner goes to the playoffs and the loser stays home for the postseason. This 95-minute episode also discusses several other minor topics not noted above and we end this episode by answering an email we received from a listener. steelersdepot.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to the Part Time Pilot Audio Ground School Podcast! This podcast releases a 2 new episodes every week on Mondays and Wednesdays. Every Monday, we release an episode that is the next lesson of our IFR Online Ground School. Every Wednesday, we release an episode that is the next lesson of our Private Pilot Online Ground School.    We are working our way through both Online Ground Schools for students to listen to ground school for FREE! If you don't want to wait for new podcasts or you don't want to hear ads or course updates, you can join us in our VIP podcast. In order to join the VIP podcast, you must purchase our Online Ground School. When you do, you'll get sent an email invite to the VIP podcast to download and listen on your favorite podcast app, plus all the amazing lifetime features inside our Online Ground Schools (lessons, videos, audio, quizzes, practice tests, flash cards, test prep PDFs, grade tracking, digital notes, trained AI instructor chat, 7-day a week email support, online study group, scholarships and more).    The #1 reason student pilots never end up becoming a private pilot is NOT due to money. The real reason is actually deeper than that. Yes, flight training is expensive. But every student pilot knows this and budgets for it when they decide to do it.   The actual #1 reason a student pilot fails is because they do not have a good, fundamental understanding of the private pilot knowledge they are meant to learn in ground school.    You see when a student does not have a good grasp of this knowledge they get to a point in their flight training where their mind just can't keep up. They start making mistakes and having to redo lessons. And THAT is when it starts getting too expensive.    This audio ground school is meant for the modern day student pilot... aka the part time student pilot. Let's face it, the majority of us have full time responsibilities on top of flight training. Whether it is a job, kids, family, school, etc. we all keep ourselves busy with the things that are important to us. And with today's economy we have to maintain that job just to pay for the training. The modern day student pilot is busy, on the go and always trying to find time throughout his or her day to stay up on their studies. The audio ground school allows them to consume high quality content while walking, running, working out, sitting in traffic, traveling, or even just a break from the boring FAR/AIM or ground school lecture.    Did I meant high quality content? The audio ground school is taken straight out of the 5-star rated Part Time Pilot Online Ground School that has had over 2000 students take and pass their Private Pilot & IFR exams with only 2 total students failing the written. That's a 99.9% success rate! And the 2 that failed? We refunded their cost of ground school and helped them pass on their second attempt. We do this by keeping ground school engaging, fun, light and consumable. We have written lessons, videos, audio lessons, live video lessons, community chats, quizzes, practice tests, flash cards, study guides, eBooks and much more.   Part Time Pilot was created to be a breath of fresh air for student pilots. To be that flight training provider that looks out for them and their needs. So that is just what we are doing with this podcast.    Private Pilot - Section 5 - Lesson #16: In this FREE Private Pilot online ground school audio lesson we cover the topic of signicant and prognosis weather charts as well as other wide area charts used by the FAA and pilots around the US for flight planning.    Links mentioned in the episode:   Aviation Weather: https://aviationweather.gov/sigwx/ 1800WXBrief: https://www.1800wxbrief.com/Website/weatherGraphics?conus=0  PPL study group: https://www.facebook.com/groups/parttimepilot  IFR study group: https://www.facebook.com/groups/parttimepilotifr/  Recommended Products & Discounts:  https://parttimepilot.com/recommended-products-for-student-pilots/ 

We review BRUEs (Brief Resolved Unexplained Events). Hosts: Ellen Duncan, MD, PhD Noumi Chowdhury, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/BRUE.mp3 Download Leave a Comment Tags: Pediatrics Show Notes What is a BRUE? BRUE stands for Brief Resolved Unexplained Event. It typically affects infants 60 days old Gestational Age: GA > 32 weeks (and Post-Conceptional Age > 45 weeks) Frequency: This is the first episode Duration: Lasted < 1 minute Intervention: No CPR performed by a trained professional Clinical Picture: Reassuring history and physical exam Management for Low Risk: Generally do not require extensive testing or admission. Prioritize safety education/anticipatory guidance. Ensure strict return precautions and close outpatient follow-up (within 24 hours). High Risk Criteria Any infant not meeting the low-risk criteria is automatically High Risk. Additional red flags include: Suspicion of child abuse History of toxin exposure Family history of sudden cardiac death Abnormal physical exam findings (trauma, neuro deficits) Management for High Risk: Requires a more thorough evaluation. Often requires hospital admission. Note: Serious underlying conditions are identified in approx. 4% of high-risk infants. Differential Diagnosis: “THE MISFITS” Mnemonic T – Trauma (Accidental or Non-accidental/Abuse) H – Heart (Congenital heart disease, dysrhythmias) E – Endocrine M – Metabolic (Inborn errors of metabolism) I – Infection (Sepsis, meningitis, pertussis, RSV) S – Seizures F – Formula (Reflux, allergy, aspiration) I – Intestinal Catastrophes (Volvulus, intussusception) T – Toxins (Medications, home exposures) S – Sepsis (Systemic infection) Workup & Diagnostics Step 1: Stabilization ABCs (Airway, Breathing, Circulation) Point-of-care Glucose Cardiorespiratory monitoring Step 2: Diagnostic Testing (For High Risk/Symptomatic Patients) Labs: VBG, CBC, Electrolytes. Imaging: CXR: Evaluate for infection and cardiothymic silhouette. EKG: Evaluate for QT prolongation or dysrhythmias. Neuro: Consider Head CT/MRI and EEG if there are concerns for trauma or seizures. Clinical Pearl: Only ~6% of diagnostic tests contribute meaningfully to the diagnosis. Be judicious—avoid “shotgunning” tests in low-risk patients. Prognosis & Outcomes Recurrence: Approximately 10% (lower than historical ALTE rates of 10-25%). Mortality: < 1%. Nearly always linked to an identifiable cause (abuse, metabolic disorder, severe infection). BRUE vs. SIDS: These are not the same. BRUE: Peaks < 2 months; occurs mostly during the day. SIDS: Peaks 2–4 months; occurs mostly midnight to 6:00 AM. Take-Home Points Diagnosis of Exclusion: You cannot call it a BRUE until you have ruled out obvious causes via history and physical. Strict Criteria: Stick strictly to the Low Risk criteria guidelines. If they miss even one (e.g., age < 60 days), they are High Risk. Education: For low-risk families, the most valuable intervention is reassurance, education, and arranging close follow-up. Systematic Approach: For high-risk infants, use a structured approach (like THE MISFITS) to ensure you don’t miss rare but reversible causes. Read More

We all want a little treat—even if we're on a budget. That desire may be part of what's shaping U.S. liquor sales; big spirits companies are seeing growth in the sales of their smaller bottles of liquor, while sales of the pricier larger sizes decline. What does that tell us about how consumers are feeling about their wallets? Host Alex Ossola discusses with Nadine Sarwat, director and equity research analyst at brokerage firm Bernstein. And finally, in this last episode of our alternative economic indicator series, WSJ investing columnist Spencer Jakab joins Alex to take stock of all four indicators in this series—Nevada employment, copper, heavy trucks and liquor—and the picture they paint about the broader U.S. economy.  Sign up for the WSJ's free What's News newsletter. Further Listening Alternative Indicators: Can Nevada Employment Predict Where the Economy is Headed? Alternative Indicators: What's Dr. Copper's Prognosis for the U.S. Economy? Alternative Indicators: What Big-Rig Truck Sales Reveal About the U.S. Economy Learn more about your ad choices. Visit megaphone.fm/adchoices

Economists and investors have long turned to copper as a reliable economic indicator: High prices meant the economy was humming, and low prices meant it wasn't. That's in part because copper is useful for so many economic activities. In fact, copper was considered such a good signal that investors gave it a nickname—Dr. Copper. But now, as high demand and tariffs affect copper prices, is the commodity's relationship with the economy becoming blurry? Host Alex Ossola discusses this with Dec Mullarkey, head of investment strategy and asset allocation at SLC Management. This is part two of our four-part series on alternative economic indicators. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

My guest is Dr. Sunita Puri, a palliative-care physician and author of That Good Night: Life and Medicine in the Eleventh Hour. We talk about what it really means to care for patients when cure is no longer the goal, why our medical system resists honest conversations about death, and how clarity and compassion can coexist at the end of life. Topics we cover:     • What palliative care really provides (beyond hospice)     • Why "more treatment" ≠ "more life"     • Prognosis, probabilities, and telling the truth kindly     • How families can ask the right questions     • Documentation that matters (and what to avoid)     • The moral distress of clinicians     • Cultural/faith factors that shape decisions     • Dignity, autonomy, and realistic hope Guest Bio: Dr. Sunita Puri is an Associate Professor of Medicine at the University of California, Irvine School of Medicine, where she is the Director of the Inpatient Palliative Care Service. She has written for The New Yorker, The New York Times, and The Atlantic, among other publications. She is the author of That Good Night: Life and Medicine in the Eleventh Hour, a critically acclaimed literary memoir examining her journey to the practice of palliative medicine, and her quest to help patients and families redefine what it means to live and die well in the face of serious illness.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners.This episode covers Functional Neurological Disorder with Dr. Patricia Rosebush. Dr. Rosebush is a Professor in the Department of Psychiatry & Behavioural Neurosciences at McMaster University. She is the distinguished author of numerous articles on clinical neuroscience, including considerable work on mitochondrial disorders in mental illness and over 30 papers on catatonia, and practices consultation-liaison psychiatry at St. Joseph's Healthcare Hamilton.The learning objectives for this episode are as follows:Provide a definition and conceptual approach to FNDIdentify clinical signs and patient histories relevant to a diagnosis of FNDDescribe an approach to the treatment of FNDUnderstand the special challenges of communication and collaboration in this illnessGuest: Dr. Patricia RosebushHosts: Dr. Alastair Morrison, Dr. Kate BraithwaiteAudio editing: Dr. Alastair MorrisonShow notes: Dr. Kate BraithwaiteInterview content:(02:39) Learning objectives(03:09) Conceptualization of FND(08:30) Underlying psychological processes(09:35) Difference between FND and factitious disorder/malingering(14:54) Alexithymia(16:51) Common symptomatic presentations(18:00) Types of underlying stressors(19:17) Other risk factors for FND(22:12) Communicating with patients to address stigma(24:32) Psychotherapy in FND(29:36) Referral pathways for patients with FND(31:15) Prognosis of FND(33:09) Social media and FNDResources:Functional Neurological Disorder Society. Functional Neurological Disorder Society (FNDS). Includes a podcast and courses for physiciansFunctional Neurological Disorder (FND) – A Patient's Guide to FNDReferences:Hull, M., & Parnes, M. (2021). Tics and TikTok: Functional Tics Spread Through Social Media. Movement disorders clinical practice, 8(8), 1248–1252. https://doi.org/10.1002/mdc3.13267National Institute for Neurological Disorders and Stroke. (2024, July.) Functional Neurological Disorder.  U.S. Department of Health and Human Services, National Institutes of Health. Functional Neurologic Disorder | National Institute of Neurological Disorders and StrokePsychDB. (2024, April). Conversion Disorder (Functional Neurological Disorder. Conversion Disorder (Functional Neurological Disorder) - PsychDBRosebush, P. I., & Mazurek, M. F. (2011). Treatment of conversion disorder in the 21st century: have we moved beyond the couch?. Current treatment options in neurology, 13(3), 255–266. https://doi.org/10.1007/s11940-011-0124-yScamvougeras, A., & Castle, D. (2024). Functional Neurological Disorders: Challenging the Mainstream Agnostic Causative Position. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 69(7), 487–492. https://doi.org/10.1177/07067437241245957For more PsychEd, follow us on Instagram (@psyched.podcast),  Facebook (PsychEd Podcast), X (@psychedpodcast), and Bluesky (@psychedpodcast.bsky.social‬). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

Contributor: Alec Coston, MD Case Report Summary: A 17-year-old female involved in a motor vehicle collision presented to a rural emergency facility via personally operated vehicle. During workup and initial CT scan, the patient began rapidly decompensating with CT revealing a 1.5cm epidural hematoma with 7mm of midline shift. The patient went from being able to walk and talk to being obtunded with a blown left pupil and unresponsive. Following intubation, the patient was being prepared for transport but potential delays required immediate emergency evacuation of the hematoma via a Burr Hole. A traditional Burr Drill was not immediately available at the facility, so an improvised Burr Drill using an Intraosseous (IO) drill was used. 35mL of blood was removed from the hematoma and the patient immediately improved from a GCS of 3 to GCS of 8. The patient was transferred to a higher level of care facility, extubated the following day, and made a full neurological recovery.  Educational Pearls: What is an epidural hematoma? An epidural hematoma is a collection of blood between the dura mater (outermost layer of the meninges) and the skull, whereas a subdural hematoma is a collection of blood between the dura mater and arachnoid mater. Both can be life threatening depending on location and size. Epidural hematomas tend to be arterial, and are typically secondary to trauma and can rapidly expand, but with timely recognition and evacuation of the bleed, favorable outcomes are often possible. What are typical intracranial pressures and at what levels do they become pathologic? Typical intracranial pressure (ICP) varies by age, but past infancy and early childhood, adolescents and adults have a value typically between 8-15mmHg. Values exceeding 20mmHg become pathologic and rise exponentially with increased volume. Initial symptoms may include headache, nausea, and vomiting, but with increased pressures may progress to more life threatening symptoms such as loss of consciousness, cranial nerve palsies, pupillary constriction or dilation (sign of herniation), and respiratory irregularities. What is the takeaway in timing of epidural hematomas? Older studies show that evacuation of a hematoma with lateralizing features before the two hour mark of coma symptom onset is correlated with decreased mortality (ranging from 15-17%), but beyond 2 hours the mortality increases to well over 50%. Though mortality statistics have grown more variable, early targeted evacuation of epidural hematomas still remains critical for improved patient outcomes. In austere conditions with limited resources, improvisation with interosseous drills and needles can improve patient outcomes and achieve the target therapy for epidural hematomas. References Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien). 1988;90(3-4):111-116. doi:10.1007/BF01560563 Hawryluk GWJ, Nielson JL, Huie JR, et al. Analysis of Normal High-Frequency Intracranial Pressure Values and Treatment Threshold in Neurocritical Care Patients: Insights into Normal Values and a Potential Treatment Threshold. JAMA Neurol. 2020;77(9):1150-1158. doi:10.1001/jamaneurol.2020.1310 Pisică D, Volovici V, Yue JK, et al. Clinical and Imaging Characteristics, Care Pathways, and Outcomes of Traumatic Epidural Hematomas: A Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury Study. Neurosurgery. 2024;95(5):986-999. doi:10.1227/neu.0000000000002982 Summarized by Dan Orbidan, OMS2 | Edited by Dan Orbidan and Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/